A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder

Guastella, Adam J.; Howard, Alexandra; Dadds, Mark R.; Mitchell, Philip B.; Carson, Dean S.

doi:10.1016/j.psyneuen.2009.01.005

Cited by 339 publications

(226 citation statements)

References 39 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…As oxytocin and vasopressin systems contribute to different aspects of brain physiology in different species thus having a role in speciestypical social behaviors (Goodson, 2013), it is important to sample from a wide variety of animal systems to get a broad picture of both the potential and limitations of these systems in humans. The ability to translate appropriately across species and developmental time points becomes imperative as the enthusiasm grows for intranasal oxytocin and vasopressin therapies in various developmental disabilities and mental illness (Guastella et al, 2009(Guastella et al, , 2010Andari et al, 2010;Feifel et al, 2010;Goldman et al, 2011;Pedersen et al, 2011;Simeon et al, 2011;Hall et al, 2012). In addition to gathering data from a wide variety of species, it will be important to understand the behavioral context in which oxytocin and vasopressin function.…”

Section: Discussionmentioning

confidence: 99%

Developmental Perspectives on Oxytocin and Vasopressin

Hammock

2014

Neuropsychopharmacol

167

146

View full text Add to dashboard Cite

The related neuropeptides oxytocin and vasopressin are involved in species-typical behavior, including social recognition behavior, maternal behavior, social bonding, communication, and aggression. A wealth of evidence from animal models demonstrates significant modulation of adult social behavior by both of these neuropeptides and their receptors. Over the last decade, there has been a flood of studies in humans also implicating a role for these neuropeptides in human social behavior. Despite popular assumptions that oxytocin is a molecule of social bonding in the infant brain, less mechanistic research emphasis has been placed on the potential role of these neuropeptides in the developmental emergence of the neural substrates of behavior. This review summarizes what is known and assumed about the developmental influence of these neuropeptides and outlines the important unanswered questions and testable hypotheses. There is tremendous translational need to understand the functions of these neuropeptides in mammalian experience-dependent development of the social brain. The activity of oxytocin and vasopressin during development should inform our understanding of individual, sex, and species differences in social behavior later in life.

show abstract

Section: Discussionmentioning

confidence: 99%

Developmental Perspectives on Oxytocin and Vasopressin

Hammock

2014

Neuropsychopharmacol

167

146

View full text Add to dashboard Cite

show abstract

“…Interestingly, the AVPR1a receptor of the closely related nonapeptide vasopressin has also been associated with ASD [40][41][42]. This provisional role of OT in ASD, is further supported by two linkage studies [43,44], clinical evidence by several groups demonstrating clinical improvement in ASD following OT administration [45][46][47][48][49][50][51] (also see [52,53]) and studies showing that ASD is also associated with alterations in OT plasma levels [54].…”

Section: Oxytocin and Autism Spectrum Disorders (Asd)mentioning

confidence: 91%

Are retinoids potential therapeutic agents in disorders of social cognition including autism?

et al. 2011

View full text Add to dashboard Cite

Edited by Sergio Papa, Gianfranco Gilardi and Wilhelm JustKeywords: Autism spectrum disorder (ASD) All-trans retinoic acid (ATRA) CD38 Oxytocin Polymorphism a b s t r a c t Increasing evidence suggests that the nonapeptide, oxytocin (OT), helps shape social and affiliative behaviors not only in lower mammals but also in humans. Recently, an essential mediator of brain OT release has been discovered, ADP-ribosyl cyclase and/or CD38. We have subsequently shown that polymorphisms across the CD38 gene are associated with autism spectrum disorders (ASD). Notably, CD38 expression in lymphoblastoid cells (LBC) is reduced in cell lines derived from ASD subjects compared to parental cell lines. Intriguingly, a correlation was observed between CD38 expression and measures of social function in ASD. Finally, we have shown that all-trans retinoic acid (ATRA), a known inducer of CD38 transcription, can rescue low CD38 expressing LBC lines derived from ASD subjects and restore normal levels of transcription of this ectoenzyme providing 'proof of principle' in a peripheral model that retinoids are potential therapeutic agents in ASD. Ó 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. OxytocinClassically, the nonapeptide oxytocin (OT) has been viewed as a hypothalamic neuropeptide that is released into the general circulation from the neural lobe of the pituitary, inducing uterine contractions during parturition and milk ejection during lactation. OT is derived from a pre-prohormone precursor that is synthesized in the hypothalamus and stored in vesicles at the posterior pituitary for storage and subsequent release into the bloodstream (see [1] for comprehensive review of the oxytocin receptor system). OT and social behaviorBeyond the long-known peripheral effects of OT, a wealth of animal studies have elaborated the role of OT, or their analogues such as isotocin and vasotocin [2], in molding social behavior from fish to mammals [3]. In the past few years the role of OT has also been examined in our own species, and similar to what has been learned from animal studies, it appears that this nonapeptides also influence social behaviors in humans [4,5]. Indeed, OT has been suggested as the 'great facilitator of life' in a recent review [6].In humans, intranasal administration of OT has been shown to increase trust [7], facilitate mind-reading [8], enhance human memory for social identity [9], increase positive communication between couples [10], increase gaze to the eye region [11] and increase generosity [12]. Intriguingly, OT plasma levels have been linked to individual patterns of maternal-fetal attachment [13] and salivary OT levels were associated with bonding to own parents and inversely related to psychological distress, particularly depressive symptoms [14]. Social anxiety symptom severity, adjusted for age and gender in a healthy group of subjects, was associated with higher plasma oxytocin levels [15]. Imaging studies reinforce the role of OT in influencing human social ...

show abstract

“…Na maior parte dos estudos, foram utilizadas amostras clínicas 18,19,[27][28][29][30][31][32][33] ou amostras provenientes da população geral 23,[34][35][36][37][38][39][40][41] , e em quatro estudos 9,42-44 foram incluídas amostras mistas. Os demais estudos 20,[45][46][47][48][49][50] não descreveram a procedência da amostra utilizada.…”

Section: Resultsunclassified

“…A ocitocina foi avaliada em associação à terapia de exposição quanto à sua eficácia para o tratamento para o TAS, porém não foi percebida melhora nos sintomas de ansiedade social ou em relação à avaliação clínica global 34 . O único resultado de eficácia observado foi o aumento das representações positivas sobre si próprio em relação à tarefa de falar em público.…”

Section: Hormôniosunclassified

Tratamentos farmacológicos para o transtorno de ansiedade social: existem novos parâmetros na atualidade?

Santos¹,

Osório²,

Loureiro³

et al. 2011

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

ResumoContexto: O transtorno de ansiedade social (TAS), apesar da baixa taxa de detecção e do alto índice de comorbidades associadas, é considerado uma condição tratável. Apesar da resposta estabelecida a diversas classes de medicamentos, os algoritmos para o tratamento do TAS necessitam de atualização constante. Objetivo: Realizar revisão sistemática da literatura no que diz respeito à eficácia dos tratamentos farmacológicos relativos ao TAS, a partir de estudos controlados, conduzidos no período de 2005 a 2010. Método: Foram utilizados os indexadores eletrônicos PsycoInfo, Lilacs e Medline, utilizando-se as palavras-chave: "social phobia or social anxiety and treatment". Resultados: De acordo com critérios de inclusão adotados, 29 artigos foram incluídos e analisados. Mostram-se eficazes para o tratamento do TAS as seguintes drogas, de acordo com a classe: a) ISRSs: escitalopram, fluvoxamina, citalopram, GR205171 e sertralina; b) ISRSN: venlafaxina; c) IMAOs: fenelzina, moclobemina; d) aminoácidos: d-cicloserina; f) anticonvulsivantes: tiagabina. Conclusão: Os ISRSs e os ISRSNs têm seu uso estabelecido e ainda continuam sendo considerados primeira opção de tratamento. Porém, destaca-se o potencial futuro da d-cicloserina e dos anticonvulsivantes, com necessidade de um número maior de estudos controlados que confirmem os achado iniciais. A ação das diferentes drogas em nível neurobiológico, bem como dos tratamentos associados, necessita ainda ser mais explorada.Forni- Santos L, et al. / Rev Psiq Clín. 2011;38(6):238-46 Palavras-chave: Transtorno de ansiedade, tratamento, psicofarmacologia, fobia social, resposta ao tratamento. AbstractBackground: Social anxiety disorder (SAD), despite its low detection rates and high level of associated comorbidities, is considered a treatable condition. Although the condition's response to several drug classes is well established, the algorithms for the treatment of SAD require regular updating. Objective: To perform a systematic literature review on the efficacy of pharmacological treatments for SAD based on controlled trials published between 2005 and 2010. Method: Searches were performed in the electronic databases PsycInfo, Lilacs, and Medline using the search terms "social phobia or social anxiety and treatment". Results: In accordance with the inclusion criteria adopted, 29 articles were included and analyzed. The following drugs, grouped according to class, proved efficient to treat SAD: a) SSRIs: escitalopram, fluvoxamine, citalopram, GR205171, and sertraline; b) SNRI: venlafaxine; c) MAOIs: phenelzine, moclobemide; d) amino acids: f-cycloserine; and (e) anticonvulsants: tiagabine. Discussion: The use of SSRIs and SNRIs to treat SAD is well established and these are still considered the firstline treatment for the condition; however, evidence suggests the future potential of D-cycloserine and anticonvulsants, whose efficacy must be confirmed by further controlled trials. The action profiles of the different medications used to treat SAD at the neurobiological level,...

show abstract

A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder

Cited by 339 publications

References 39 publications

Developmental Perspectives on Oxytocin and Vasopressin

Developmental Perspectives on Oxytocin and Vasopressin

Are retinoids potential therapeutic agents in disorders of social cognition including autism?

Tratamentos farmacológicos para o transtorno de ansiedade social: existem novos parâmetros na atualidade?

Contact Info

Product

Resources

About